
Kathleen Moore
Deputy Director, Fred & Pamela Buffett Cancer Center · University of Nebraska Medical Center College of Medicine
Credentials: · · · · ·
History
PresentFred & Pamela Buffett Cancer Center · University of Nebraska Medical Center College of Medicine
PresentPhase 1 Oncology Trials · University of Nebraska Medical Center College of Medicine

- 2010–2013
OU College of Medicine
- 2003–2006
University Health Center of Pittsburgh
Research
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
New England Journal of Medicine · 2018 · First of 21 authors · 2,290 citations
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
New England Journal of Medicine · 2019 · 726 citations
Recent advances and clinical applications of deep learning in medical image analysis
Review · Medical Image Analysis · 2022 · 535 citations

46 papers
- RC
45 papers

44 papers
- CA
33 papers

31 papers · 23 as a resident

28 papers

27 papers

22 papers
Grants
- 2018–2028
Stephenson Cancer Center - Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $1.6M · University of Oklahoma Hlth Sciences Ctr
- 2024–2027
National Cancer Institute · UG1
PI · $2.1M · University of Oklahoma Hlth Sciences Ctr
- 1997–2027
Buffett Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $629.5K · University of Nebraska Medical Center
- 2022–2026
Oklahoma Center of Medical Imaging for Translational Cancer Research
National Institute of General Medical Sciences · P20
Project lead · $1.4M · University of Oklahoma
Clinical trials
- 2026–2029
Evaluating the Addition of OK-1 Weekly Paclitaxel in Patients With Endometrial Cancer
Principal investigator · Not yet recruiting · Phase 2
University of Oklahoma
- 2022–2024
A Study of Navicixizumab in Patients With Platinum Resistant Ovarian Cancer
Principal investigator · Unknown · Phase 3
OncXerna Theraputics, Inc.
- 2019–2020
Principal investigator · Terminated · Phase 2
pharmaand GmbH
- 2018–2026
Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer
Principal investigator · Active not recruiting · Phase 2
University of Oklahoma


